UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 63

Sortiert nach

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

Annals of oncology, 2016-07, Vol.27 (7), p.1304-1311

2016

Link zum Volltext

Verfügbarkeit prüfen

MA04.08 The Effect of Packed Red Blood Cell Transfusions on the Clinical Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S146-S146

2021

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

2015

Link zum Volltext

Verfügbarkeit prüfen

1465P Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) in the United States

Annals of oncology, 2022-09, Vol.33, p.S1216

2022

Link zum Volltext

Verfügbarkeit prüfen

682P Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)

Annals of oncology, 2021-09, Vol.32, p.S702-S702

2021

Link zum Volltext

Verfügbarkeit prüfen

1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study

Annals of oncology, 2022-09, Vol.33, p.S1349

2022

Link zum Volltext

Verfügbarkeit prüfen

2281P Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)

Annals of oncology, 2023-10, Vol.34, p.S1169-S1170

2023

Link zum Volltext

Verfügbarkeit prüfen

632P Differential transcriptomic profiling of BCL2-related genes in primary tumor (PT) and metastatic sites (MS) of prostate cancer (PCa)

Annals of oncology, 2021-09, Vol.32, p.S665-S665

2021

Link zum Volltext

Verfügbarkeit prüfen

688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features

Annals of oncology, 2021-09, Vol.32, p.S705-S705

2021

Link zum Volltext

Verfügbarkeit prüfen

PCN92 Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

Value in health, 2021-06, Vol.24, p.S36-S36

2021

Link zum Volltext

Verfügbarkeit prüfen

PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

Value in health, 2021-06, Vol.24, p.S28-S29

2021

Link zum Volltext

Verfügbarkeit prüfen

Re: Treatment Trends and Outcomes for Patients with Lymph Node-Positive Cancer of the Penis

The Journal of urology, 2020-05, Vol.203 (5), p.879-880

Chang, Sam S

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2018-06, Vol.36 (16), p.1588-1593

2018

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

Annals of oncology, 2016-10, Vol.27, p.vi291-vi291

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial

Annals of oncology, 2016-10, Vol.27, p.vi284-vi284

2016

Link zum Volltext

Verfügbarkeit prüfen

MA1 - Non-Adherence is Associated with Poorer Health Outcomes Among Women Currently Treated for Breast Cancer with Oral Endocrine Therapy

Value in health, 2014-05, Vol.17 (3), p.A7-A8

2014

Link zum Volltext

Verfügbarkeit prüfen

Non-Adherence is Associated with Poorer Health Outcomes Among Women Currently Treated for Breast Cancer with Oral Endocrine Therapy

Value in health, 2014-05, Vol.17 (3), p.A7-A8

2014

Link zum Volltext

Verfügbarkeit prüfen

Plasmalemmal Vesicle Associated Protein-1 Is a Novel Marker Implicated in Brain Tumor Angiogenesis

Clinical cancer research, 2005-11, Vol.11 (21), p.7643-7650

2005

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Intentional and Unintentional Non-Adherence and Associated Health Utilities among Women Receiving Oral Treatments for Breast Cancer

Value in health, 2016-05, Vol.19 (3), p.A8-A9

2016

Link zum Volltext

Verfügbarkeit prüfen

MA3 - Predictors of Intentional and Unintentional Non-Adherence and Associated Health Utilities among Women Receiving Oral Treatments for Breast Cancer

Value in health, 2016-05, Vol.19 (3), p.A8-A9

2016

Link zum Volltext

Verfügbarkeit prüfen

The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

Value in health, 2016, Vol.19 (1), p.88-98

2016

Link zum Volltext

Verfügbarkeit prüfen

All the darkness we don’t see

American journal of obstetrics and gynecology, 2017-02, Vol.216 (2), p.135.e1-135.e5

2017

Link zum Volltext

Verfügbarkeit prüfen

TEMPORARY REMOVAL: Long-term patient reported outcomes from a phase III randomized prospective trial of conventional versus hypofractionated radiotherapy for localized prostate cancer

International journal of radiation oncology, biology, physics, 2016

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Journal of clinical oncology, 2020-06, Vol.38 (16), p.1797-1806

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(62)
Tagungsberichte
(1)

Sprache

Englisch
(63)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

MA04.08 The Effect of Packed Red Blood Cell Transfusions on the Clinical Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

1465P Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) in the United States

682P Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)

1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study

2281P Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)

632P Differential transcriptomic profiling of BCL2-related genes in primary tumor (PT) and metastatic sites (MS) of prostate cancer (PCa)

688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

PCN92 Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

Re: Treatment Trends and Outcomes for Patients with Lymph Node-Positive Cancer of the Penis

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial

MA1 - Non-Adherence is Associated with Poorer Health Outcomes Among Women Currently Treated for Breast Cancer with Oral Endocrine Therapy

Non-Adherence is Associated with Poorer Health Outcomes Among Women Currently Treated for Breast Cancer with Oral Endocrine Therapy

Plasmalemmal Vesicle Associated Protein-1 Is a Novel Marker Implicated in Brain Tumor Angiogenesis

Predictors of Intentional and Unintentional Non-Adherence and Associated Health Utilities among Women Receiving Oral Treatments for Breast Cancer

MA3 - Predictors of Intentional and Unintentional Non-Adherence and Associated Health Utilities among Women Receiving Oral Treatments for Breast Cancer

The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

All the darkness we don’t see

TEMPORARY REMOVAL: Long-term patient reported outcomes from a phase III randomized prospective trial of conventional versus hypofractionated radiotherapy for localized prostate cancer

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Suchergebnisse filtern